Washington, May 11, 2021 (GLOBE NEWSWIRE) — New Frontier Data (https://NewFrontierData.com), the global authority in data, analytics and business intelligence on the cannabis industry, releases its latest industry report, Medical Cannabis & Pharmaceuticals: Growth & Disruption in U.S. Healthcare, highlighting medical cannabis patients as a consumer group with distinct reasons for consumption that vary greatly from those of recreational users. The rise of cannabis in the wellness space, the legal market expansion, and consumer sentiment shifting towards medical cannabis as a viable alternative to prescription medications are contributing to potential disruption of the pharmaceutical market. One of the key findings in this report is that the U.S. Medical Cannabis Market is projected to hit $16 billion by 2025.
Incorporating New Frontier Data’s extensive analysis on the cannabis consumer, the report delivers an in-depth and comprehensive assessment of medical cannabis preferences and behaviors, consumer purchasing and consumption habits, and the potential impact on the pharmaceutical industry.
“The pharmaceutical sectors across Europe, Asia and North America are making strides into the recognition and application of cannabis relative to more traditional medicine, making this a critical time to best understand what the patient needs and wants, not to mention why,” noted New Frontier Data Founder and Executive Chair, Giadha A. DeCarcer. “Given the current opioid crisis in the United States and beyond, we expect increased, if not improved, collaboration and communication between the medical community and cannabis research, with an emphasis on efficacy optimization and better medicinal alignment with patient behavior.”
Related: Global Cannabis Market to Reach $47 Billion by 2025
Key Findings of the Report Include:
Growth of Medical Cannabis & Market Opportunity:
- 41% of U.S. cannabis consumers self-identify as medical consumers (versus recreational users) and of those, 44% are between the ages of 25-44 and 36% are aged 45-64 highlighting important demographics for medical cannabis brands.
- Nearly half of medical consumers (45%) identify smokable cannabis as their preferred product form while 24% prefer edibles and beverages, key insight for retailers and operators.
Cannabis as an Alternative for Prescription Drugs:
- Leading prescription types replaced by medical cannabis: anticonvulsants (72%), glaucoma medication (71%), anti-migraine medication (65%), nausea suppressants (65%), and ADD/ADHD (62%).
- Consumer drivers for choosing cannabis over pharmaceuticals: 51% want more natural treatment options; 48% want to reduce or cease prescription drug use; and 29% indicate pharmaceuticals were ineffective.
- Patients reported using less prescription medications since beginning treatments with medical cannabis in the following drug categories: opiates (68%), anxiety medications (51%) and sleep aids (55%).
A FREE copy of the Medical Cannabis & Pharmaceuticals: Growth & Disruption in U.S. Healthcare report can be downloaded here: https://hubs.la/H0N0qBl0.
U.S. Medical Cannabis Market Projected to Hit $16 Billion by 2025
About New Frontier Data:
New Frontier Data is the premier data, analytics and technology firm specializing in the global cannabis industry, delivering solutions that enable investors, operators, advertisers, brands, researchers and policy makers to assess, understand, engage and transact with the cannabis industry and its consumers.
Our mission is to inform policy and commercial activity for the global legal cannabis industry. We maintain a neutral position on the merits of cannabis legalization through comprehensive and transparent data analysis and projections that shape industry trends, dynamics, demand and opportunity drivers. Founded in 2014, New Frontier Data is headquartered in Washington, D.C. with a presence in Europe, Latin America and Africa. For more information about New Frontier Data, please visit us at https://www.newfrontierdata.com/.
U.S. Medical Cannabis Market Projected to Hit $16 Billion by 2025
About Cannin: Your Cannabis Stocks Resource
78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.
Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. We aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021.
Use Cannin as your resource for:
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.
Are you looking to buy stock in hemp companies or marijuana companies for 2021? Interested in new penny hemp stock companies? Looking for the best Canadian cannabis stocks to invest in? Looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.
Are you interested in cannabis stocks like Curaleaf, Trulieve, Aurora Cannabis, Charlotte’s Web, Canopy Growth, or Hemp Inc.?
Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.
- +25% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
We’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best cannabis stocks – we’ll show you how at cannin.com.
